Sovaldi and Dermatitis - allergic - a phase IV clinical study of FDA data
Summary:
We study 12,916 people who take Sovaldi (sofosbuvir) or have Dermatitis - allergic. No report of Dermatitis - allergic is found in people who take Sovaldi.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Sovaldi?
Sovaldi has active ingredients of sofosbuvir. eHealthMe is studying from 12,697 Sovaldi users. Check the latest studies of Sovaldi.
What is Dermatitis - Allergic?
Dermatitis - allergic (inflammation of the skin due allergic reaction) is found to be associated with 3 conditions by eHealthMe. Check the latest studies of Dermatitis - allergic.
No report is found.
Do you take Sovaldi and have Dermatitis - allergic?
- Check whether Dermatitis - allergic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Sovaldi:
- Sovaldi (12,697 reports)
Dermatitis - allergic treatments and more:
- Dermatitis - allergic (219 reports)
How severe was Dermatitis - allergic and when was it recovered:
Expand to all the drugs that have ingredients of sofosbuvir:
Browse all side effects of Sovaldi:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Dermatitis - allergic:
Browse all the conditions that are associated with Dermatitis - allergic:
How the study uses the data?
The study uses data from the FDA. It is based on sofosbuvir (the active ingredients of Sovaldi) and Sovaldi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Dilaudid and Proair Hfa - now
- Could Indapamide cause Cough Aggravated? - now
- Antiinflammatory Therapy and Adverse Drug Reaction - a second ago
- Chronic Lymphocytic Leukaemia and Eye Disorder - 16 seconds ago
- Drug interactions of Dilaudid and Colchicine - 18 seconds ago
- Androgenetic Alopecia and Cerebral Infarction - 18 seconds ago
- Hypersensitivity and Toothaches - 19 seconds ago
- Could Repaglinide cause Pneumonia? - 27 seconds ago
- Drug interactions of Probiotic and Latisse - 35 seconds ago
- Urination - Painful and Gastroesophageal Reflux Disease - 41 seconds ago